Biogen Inc (BIIB NASDAQ) stock market data APIs
$181.1062
1.15(0.6%)
as of December 5, 2025
Try our APIs with
free plan!
Biogen Inc Financial Data Overview
Price chart is built with
Anychart
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Prev. Close
181.1062
Open
182.2551
High
182.9146
Low
180.4836
52 wk Range
110.04-185.17
Market Cap
26 597 M
P/E Ratio
16.5269
Shares Outstanding
147 M
Revenue
10 066 M
EPS
4.81
Beta
0.128
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Biogen Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biogen Inc data using free add-ons & libraries
Get Biogen Inc Fundamental Data
Biogen Inc Fundamental data includes:
- Net Revenue: 10 066 M
- EBITDA: 3 409 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: 3.85
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biogen Inc News
New
Is Alnylam Pharmaceuticals a Millionaire Maker?
Key Points Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising. Whether or not Alnylam is a millionaire maker, the stock should be able to genera...
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)?
In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet ...
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?
Key Points Novo Nordisk's semaglutide failed in pivotal studies as a treatment for Alzheimer's disease. This isn't a significant obstacle to the drugmaker's prospects, despite what the market reactio...
Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Revolution Medicines, Inc. (RVMD). Shares have added about 27.9% in that time frame, outperforming the S&P 500. Will the recent positive t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
